Clinical Trial Update: Study of Power Doppler Ultrasound (PDUS) to Measure Response of Secukinumab Treatment in Patients With Active Psoriatic Arthritis (PsA) [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating Power Doppler Ultrasound to measure response to secukinumab in active psoriatic arthritis; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-12-07